Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.47 |
| ▸ | TMPRSS15 | P98073 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | IKBKB | O14920 | 1/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30547524 | 1.00 | KDM4E (0.60) | KDM4EMAPTMEN1KMT2ASMN1; SMN2 | |
| Bromide SCHEMBL30338927 | 0.99 | KDM4E (0.58) | KDM4EMAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL25296404 | 0.84 | PIK3CA (0.51) | KDM4ELMNATMPRSS15PIK3CAHTT | |
| SCHEMBL25245322 | 0.83 | KDM4E (0.64) | KDM4EMAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL22533443 | 0.83 | KDM4E (0.64) | KDM4EMAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL25818908 | 0.80 | KDM4E (0.55) | KDM4EMAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL25818614 | 0.79 | KDM4E (0.58) | KDM4EMEN1KMT2ASMN1; SMN2LMNA | |
| Trifluoroacetic Acid SCHEMBL30338868 | 0.78 | DPP4 (0.49) | KDM4ELMNAPIK3CACYP2D6HTT | |
| SCHEMBL4309526 | 0.78 | PRKD1 (0.60) | PIK3CA | |
| SCHEMBL20729064 | 0.78 | KDM4E (0.67) | KDM4EMEN1KMT2ASMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219937-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | SANOFI (FR) | 2023-07-13 | — | — | US | disclosed |
| US-20230219937-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | SANOFI (FR) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219937-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | RIPK1, RIPK4, RIPK2 | KDM4E 2270/4885MAPT 3860/4885MEN1 4787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.